Published in Kidney Int on September 01, 2003
Systematic review of randomized clinical trials on the use of hydroxyethyl starch for fluid management in sepsis. BMC Emerg Med (2008) 1.25
Comparison of the effects of gelatin, Ringer's solution and a modern hydroxyl ethyl starch solution after coronary artery bypass graft surgery. Cardiovasc J Afr (2012) 1.04
Hydroxyethyl starch versus Ringer solution in cardiopulmonary bypass prime solutions (a randomized controlled trial). J Cardiothorac Surg (2008) 0.96
Colloid-induced kidney injury: experimental evidence may help to understand mechanisms. Crit Care (2009) 0.88
Early fluid resuscitation with hyperoncotic hydroxyethyl starch 200/0.5 (10%) in severe burn injury. Crit Care (2010) 0.84
Hyperbranched polyglycerol as a colloid in cold organ preservation solutions. PLoS One (2015) 0.78
Impact of perioperative administration of 6 % hydroxyethyl starch 130/0.4 on serum cystatin C-derived renal function after radical prostatectomy: a single-centre retrospective study. BMC Anesthesiol (2016) 0.78
Cold preservation with hyperbranched polyglycerol-based solution improves kidney functional recovery with less injury at reperfusion in rats. Am J Transl Res (2017) 0.75
Pro/con debate: should synthetic colloids be used in patients with septic shock? Crit Care (2009) 0.75
Acid-base and electrolyte status during normovolemic hemodilution with succinylated gelatin or HES-containing volume replacement solutions in rats. PLoS One (2013) 0.75
The effects of tranexamic acid and 6% hydroxyethyl starch (HES) solution (130/0.4) on postoperative bleeding in coronary artery bypass graft (CABG) surgery. Int J Clin Exp Med (2015) 0.75
Stable creatinine clearance using large-dose HES versus reduced GFR. Kidney Int (2004) 0.75
Perioperative fluid and electrolyte management in cardiac surgery: a review. J Extra Corpor Technol (2012) 0.75
Rosuvastatin to prevent vascular events in men and women with elevated C-reactive protein. N Engl J Med (2008) 43.36
Variable selection for propensity score models. Am J Epidemiol (2006) 10.68
Reduction in C-reactive protein and LDL cholesterol and cardiovascular event rates after initiation of rosuvastatin: a prospective study of the JUPITER trial. Lancet (2009) 10.52
A review of uses of health care utilization databases for epidemiologic research on therapeutics. J Clin Epidemiol (2005) 8.77
Long-term, low-intensity warfarin therapy for the prevention of recurrent venous thromboembolism. N Engl J Med (2003) 8.65
Risk of death in elderly users of conventional vs. atypical antipsychotic medications. N Engl J Med (2005) 8.44
Vitamins E and C in the prevention of cardiovascular disease in men: the Physicians' Health Study II randomized controlled trial. JAMA (2008) 8.32
High-dimensional propensity score adjustment in studies of treatment effects using health care claims data. Epidemiology (2009) 7.40
A review of the application of propensity score methods yielded increasing use, advantages in specific settings, but not substantially different estimates compared with conventional multivariable methods. J Clin Epidemiol (2005) 7.31
Long-term persistence in use of statin therapy in elderly patients. JAMA (2002) 7.19
Accuracy of Medicare claims-based diagnosis of acute myocardial infarction: estimating positive predictive value on the basis of review of hospital records. Am Heart J (2004) 6.57
Results of multivariable logistic regression, propensity matching, propensity adjustment, and propensity-based weighting under conditions of nonuniform effect. Am J Epidemiol (2005) 6.20
A randomized study of how physicians interpret research funding disclosures. N Engl J Med (2012) 5.47
Multivitamins in the prevention of cancer in men: the Physicians' Health Study II randomized controlled trial. JAMA (2012) 5.25
Vitamins E and C in the prevention of prostate and total cancer in men: the Physicians' Health Study II randomized controlled trial. JAMA (2008) 5.13
Antidepressant use in pregnancy and the risk of cardiac defects. N Engl J Med (2014) 4.99
Nonadherence to adjuvant tamoxifen therapy in women with primary breast cancer. J Clin Oncol (2003) 4.95
Risk of death and cardiovascular events in initially healthy women with new-onset atrial fibrillation. JAMA (2011) 4.73
Self-management education programs in chronic disease: a systematic review and methodological critique of the literature. Arch Intern Med (2004) 4.68
Full coverage for preventive medications after myocardial infarction. N Engl J Med (2011) 4.51
The comparative safety of analgesics in older adults with arthritis. Arch Intern Med (2010) 4.47
Cardiovascular benefits and diabetes risks of statin therapy in primary prevention: an analysis from the JUPITER trial. Lancet (2012) 4.46
Multivitamins in the prevention of cardiovascular disease in men: the Physicians' Health Study II randomized controlled trial. JAMA (2012) 4.40
New FDA breakthrough-drug category--implications for patients. N Engl J Med (2014) 4.30
Adherence to therapy with oral antineoplastic agents. J Natl Cancer Inst (2002) 4.16
HDL cholesterol and residual risk of first cardiovascular events after treatment with potent statin therapy: an analysis from the JUPITER trial. Lancet (2010) 4.07
Outcomes of reference pricing for angiotensin-converting-enzyme inhibitors. N Engl J Med (2002) 4.07
Depression and risk of sudden cardiac death and coronary heart disease in women: results from the Nurses' Health Study. J Am Coll Cardiol (2009) 3.99
A combined comorbidity score predicted mortality in elderly patients better than existing scores. J Clin Epidemiol (2011) 3.98
Anticonvulsant medications and the risk of suicide, attempted suicide, or violent death. JAMA (2010) 3.85
Adherence to lipid-lowering therapy and the use of preventive health services: an investigation of the healthy user effect. Am J Epidemiol (2007) 3.82
The epidemiology of prescriptions abandoned at the pharmacy. Ann Intern Med (2010) 3.78
The implications of choice: prescribing generic or preferred pharmaceuticals improves medication adherence for chronic conditions. Arch Intern Med (2006) 3.64
Burden of changes in pill appearance for patients receiving generic cardiovascular medications after myocardial infarction: cohort and nested case-control studies. Ann Intern Med (2014) 3.62
Effect of smoking on comparative efficacy of antiplatelet agents: systematic review, meta-analysis, and indirect comparison. BMJ (2013) 3.43
The quality of pharmacologic care for vulnerable older patients. Ann Intern Med (2004) 3.34
Analytic strategies to adjust confounding using exposure propensity scores and disease risk scores: nonsteroidal antiinflammatory drugs and short-term mortality in the elderly. Am J Epidemiol (2005) 3.33
The implications of therapeutic complexity on adherence to cardiovascular medications. Arch Intern Med (2011) 3.27
Rethinking the use of physicians as hired expert lecturers. Ann Intern Med (2014) 3.22
Blood pressure and risk of developing type 2 diabetes mellitus: the Women's Health Study. Eur Heart J (2007) 3.21
Drug-review deadlines and safety problems. N Engl J Med (2008) 3.16
Variations in pill appearance of antiepileptic drugs and the risk of nonadherence. JAMA Intern Med (2013) 3.13
Cardiovascular outcomes and mortality in patients using clopidogrel with proton pump inhibitors after percutaneous coronary intervention or acute coronary syndrome. Circulation (2009) 3.09
Balancing innovation, access, and profits--market exclusivity for biologics. N Engl J Med (2009) 3.08
Tumor necrosis factor alpha antagonist use and cancer in patients with rheumatoid arthritis. Arthritis Rheum (2006) 3.04
High-density lipoprotein cholesterol, size, particle number, and residual vascular risk after potent statin therapy. Circulation (2013) 3.03
Confounding control in healthcare database research: challenges and potential approaches. Med Care (2010) 3.01
Relationship between selective cyclooxygenase-2 inhibitors and acute myocardial infarction in older adults. Circulation (2004) 2.98
University-based science and biotechnology products: defining the boundaries of intellectual property. JAMA (2005) 2.95
Compliance with osteoporosis medications. Arch Intern Med (2005) 2.91
Hetastarch and bleeding complications after coronary artery surgery. Chest (2003) 2.87
Noncompliance with antihypertensive medications: the impact of depressive symptoms and psychosocial factors. J Gen Intern Med (2002) 2.85
Nonsteroidal anti-inflammatory drug use and acute myocardial infarction. Arch Intern Med (2002) 2.82
Selective prescribing led to overestimation of the benefits of lipid-lowering drugs. J Clin Epidemiol (2006) 2.81
Internet marketing of herbal products. JAMA (2003) 2.77
Economic implications of evidence-based prescribing for hypertension: can better care cost less? JAMA (2004) 2.77
Treatment effects in the presence of unmeasured confounding: dealing with observations in the tails of the propensity score distribution--a simulation study. Am J Epidemiol (2010) 2.74
Inhibition of clinical benefits of aspirin on first myocardial infarction by nonsteroidal antiinflammatory drugs. Circulation (2003) 2.73
The comparative safety of opioids for nonmalignant pain in older adults. Arch Intern Med (2010) 2.71
Comparative mortality risk of anemia management practices in incident hemodialysis patients. JAMA (2010) 2.71
Sending pharma better signals. Science (2005) 2.69
Identification of individuals with CKD from Medicare claims data: a validation study. Am J Kidney Dis (2005) 2.65
Improved comorbidity adjustment for predicting mortality in Medicare populations. Health Serv Res (2003) 2.65
Characteristics of clinical trials to support approval of orphan vs nonorphan drugs for cancer. JAMA (2011) 2.60
Improvements in long-term mortality after myocardial infarction and increased use of cardiovascular drugs after discharge: a 10-year trend analysis. J Am Coll Cardiol (2008) 2.58
Excess weight and the risk of incident coronary heart disease among men and women. Obesity (Silver Spring) (2009) 2.56
Performance of propensity score calibration--a simulation study. Am J Epidemiol (2007) 2.56
Adjusting effect estimates for unmeasured confounding with validation data using propensity score calibration. Am J Epidemiol (2005) 2.55
Practical, legal, and ethical issues in expanded access to investigational drugs. N Engl J Med (2015) 2.53
Medicaid prior-authorization programs and the use of cyclooxygenase-2 inhibitors. N Engl J Med (2004) 2.52
Incorporation of clustering effects for the Wilcoxon rank sum test: a large-sample approach. Biometrics (2003) 2.49